Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R092670SCH3006 | Other Identifier | Janssen Scientific Affairs, LLC |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.
The primary objective of this study is to compare the efficacy of paliperidone palmitate with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated. Protocol-defined treatment failure is defined as arrest, psychiatric hospitalization, increase in psychiatric services to prevent imminent hospitalization, discontinuation of antipsychotic treatment due to inadequate efficacy, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to safety or tolerability or completed suicide. Protocol was amended on March 15, 2011 to reflect changes in the inclusion/exclusion criteria as well as the study objectives. Patients will receive either paliperidone palmitate 78, 117, 156, or 234 mg monthly by injection for fifteen months OR oral aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone at doses selected by the study doctor.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 001 | Experimental | paliperidone palmitate 78 117 156 or 234 mg monthly injection for 15 months |
|
| 002 | Active Comparator | aripiprazole flexible dosing as prescribed by the study doctor for 15 months |
|
| 003 | Active Comparator | haloperidole flexible dosing as prescribed by the study doctor for 15 months |
|
| 004 | Active Comparator | olanzapine flexible dosing as prescribed by the study doctor for 15 months |
|
| 005 | Active Comparator | paliperidone flexible dosing as prescribed by the study doctor for 15 months |
|
| 006 | Active Comparator | perphenazine flexible dosing as prescribed by the study doctor for 15 months |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| paliperidone | Drug | flexible dosing as prescribed by the study doctor for 15 months |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Time to First Treatment Failure | Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. | From date of randomization up to Month 15 |
| Percentage of Participants in Each Event Category of First Treatment Failure | First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed. | From date of randomization up to Month 15 |
| Measure | Description | Time Frame |
|---|---|---|
| Time to First Psychiatric Hospitalization or Arrest/Incarceration | A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Janssen Scientific Affairs, LLC Clinical Trial | Janssen Scientific Affairs, LLC | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bullhead City | Arizona | United States | ||||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37756123 | Derived | Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, Sliwa JK, Najarian DM, Starr HL. Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia: An Integrated Patient-Level Post Hoc Analysis. J Clin Psychiatry. 2023 Sep 25;84(6):23m14788. doi: 10.4088/JCP.23m14788. | |
| 33988924 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Paliperidone Palmitate | Intramuscular injection, 234 milligram (mg) on Day 1, 156 mg on Day 8, followed by flexible monthly maintenance dosing as per investigator's discretion starting on Day 38 up to 15 months. |
| FG001 | Oral Antipsychotics |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 007 | Active Comparator | quetiapine flexible dosing as prescribed by the study doctor for 15 months |
|
| 008 | Active Comparator | risperidone flexible dosing as prescribed by the study doctor for 15 months |
|
| risperidone |
| Drug |
flexible dosing as prescribed by the study doctor for 15 months |
|
| haloperidole | Drug | flexible dosing as prescribed by the study doctor for 15 months |
|
| perphenazine | Drug | flexible dosing as prescribed by the study doctor for 15 months |
|
| aripiprazole | Drug | flexible dosing as prescribed by the study doctor for 15 months |
|
| quetiapine | Drug | flexible dosing as prescribed by the study doctor for 15 months |
|
| paliperidone palmitate | Drug | 78, 117, 156, or 234 mg monthly injection for 15 months |
|
| olanzapine | Drug | flexible dosing as prescribed by the study doctor for 15 months |
|
| From date of randomization up to Month 15 |
| Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration | The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score <=30 represents poor function that requires intensive supervision. | Baseline up to Month 15 |
| Time to First Psychiatric Hospitalization | A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization." | From date of randomization up to Month 15 |
| Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration | The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness. | Baseline up to Month 15 |
| Tuscon |
| Arizona |
| United States |
| Little Rock | Arkansas | United States |
| Anaheim | California | United States |
| Escondido | California | United States |
| Glendale | California | United States |
| Imperial | California | United States |
| Long Beach | California | United States |
| National City | California | United States |
| Oakland | California | United States |
| Oceanside | California | United States |
| Pico Rivera | California | United States |
| Riverside | California | United States |
| San Bernadino | California | United States |
| San Diego | California | United States |
| San Fran Cisco | California | United States |
| New Britain | Connecticut | United States |
| New London | Connecticut | United States |
| Leesburg | Florida | United States |
| Miami | Florida | United States |
| Miami Gardens | Florida | United States |
| Pensacola | Florida | United States |
| Tamarac | Florida | United States |
| Tampa | Florida | United States |
| Honolulu | Hawaii | United States |
| Chicago | Illinois | United States |
| Hoffman Estates | Illinois | United States |
| Naperville | Illinois | United States |
| Springfield | Illinois | United States |
| Wichita | Kansas | United States |
| Witchita | Kansas | United States |
| New Orleans | Louisiana | United States |
| Shreveport | Louisiana | United States |
| Flowood | Mississippi | United States |
| Kansas City | Missouri | United States |
| Omaha | Nebraska | United States |
| Las Vegas | Nevada | United States |
| Paramus | New Jersey | United States |
| Willingboro | New Jersey | United States |
| Buffalo | New York | United States |
| New York | New York | United States |
| Cleveland | Ohio | United States |
| Middleburg Heights | Ohio | United States |
| Willoughby | Ohio | United States |
| Oklahoma City | Oklahoma | United States |
| Allentown | Pennsylvania | United States |
| Philadelphia | Pennsylvania | United States |
| Charleston | South Carolina | United States |
| Nashville | Tennessee | United States |
| DeSoto | Texas | United States |
| Irving | Texas | United States |
| San Antonio | Texas | United States |
| Wharton | Texas | United States |
| Bothell | Washington | United States |
| Spokane | Washington | United States |
| Rio Piedras | Puerto Rico |
| Bell Lynum KS, Henderson DC, Wright HJ, Gogate JP, Kim E. Treatment Effect With Paliperidone Palmitate Compared With Oral Antipsychotics in Black/African American Patients With Schizophrenia and a History of Criminal Justice System Involvement: A Post Hoc Analysis of the PRIDE Study. J Clin Psychiatry. 2021 Feb 23;82(2):20m13356. doi: 10.4088/JCP.20m13356. |
| 26742509 | Derived | Alphs L, Mao L, Lynn Starr H, Benson C. A pragmatic analysis comparing once-monthly paliperidone palmitate versus daily oral antipsychotic treatment in patients with schizophrenia. Schizophr Res. 2016 Feb;170(2-3):259-64. doi: 10.1016/j.schres.2015.12.012. Epub 2015 Dec 29. |
| 26403322 | Derived | Alphs L, Bossie C, Mao L, Lee E, Starr HL. Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement. Early Interv Psychiatry. 2018 Feb;12(1):55-65. doi: 10.1111/eip.12271. Epub 2015 Sep 25. |
| 25938474 | Derived | Alphs L, Benson C, Cheshire-Kinney K, Lindenmayer JP, Mao L, Rodriguez SC, Starr HL. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015 May;76(5):554-61. doi: 10.4088/JCP.14m09584. |
| 25375367 | Derived | Alphs L, Mao L, Rodriguez SC, Hulihan J, Starr HL. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry. 2014 Dec;75(12):1388-93. doi: 10.4088/JCP.13m08965. |
One of 7 oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone) that the investigator specified as appropriate for the participant was administered as per clinical practice for up to 15 months. |
| Treated |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
Intent to Treat (ITT) population included all participants who were randomly assigned to treatment and who received at least 1 dose of their randomly assigned study treatment.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Paliperidone Palmitate | Intramuscular injection, 234 milligram (mg) on Day 1, 156 mg on Day 8, followed by flexible monthly maintenance dosing as per investigator's discretion starting on Day 38 up to 15 months. |
| BG001 | Oral Antipsychotics | One of 7 oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone) that the investigator specified as appropriate for the participant was administered as per clinical practice for up to 15 months. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Baseline Personal and Social Performance (PSP) Total Score | The PSP score assesses degree of difficulty within 4 domains of behavior using 6-point Likert scale(0=absent to 5=very severe).The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores=better functioning. | Mean | Standard Deviation | Units on a scale |
| ||||||||||||||
| Baseline Clinical Global Impression - Severity (CGI-S) Total Score | The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness. | Mean | Standard Deviation | Units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Time to First Treatment Failure | Time to first treatment failure was the time from participant randomization to the first treatment failure, which was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. | Explanatory Intent-to-Treat (eITT) population included all ITT participants who had their study assessments for time period between randomization date and eITT end point. The eITT end point for paliperidone palmitate was the last injection date+28 days and for oral antipsychotics was the last prescription date + the number of days' supply + 1 day. | Posted | Median | 95% Confidence Interval | Days | From date of randomization up to Month 15 |
|
|
| ||||||||||||||||||||||||||||
| Secondary | Time to First Psychiatric Hospitalization or Arrest/Incarceration | A time to parameter looking only at 2 component events of treatment failure: arrest or incarceration, and psychiatric hospitalization. An arrest was defined as the taking of a participant into custody by legal authority, for any reason. Incarceration was defined as involuntary confinement by an officer of the law. Psychiatric hospitalization was an inpatient psychiatric hospitalization that occurred due to the participant's clinically significant worsening of symptoms of schizophrenia. | eITT population included all ITT participants who had their study assessments for time period between randomization date and eITT end point. The eITT end point for paliperidone palmitate was the last injection date+28 days and for oral antipsychotics was the last prescription date + the number of days' supply + 1 day. | Posted | Median | 95% Confidence Interval | Days | From date of randomization up to Month 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Personal and Social Performance (PSP) Total Score During Overall Treatment Duration | The PSP score assesses the degree of difficulty a participant exhibit over a 1 month period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The investigators rate participants' degree of difficulty in each of the 4 domains using a 6-point Likert scale (from 0=absent to 5=very severe). The domain ratings were then transformed to PSP total score ranging from 1 to 100. Higher PSP total scores denote better functioning. A score between 71 and 100 represents normal to mild degree of dysfunction; a score between 31 and 70 represents varying degree of difficulty; and a score <=30 represents poor function that requires intensive supervision. | eITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. | Posted | Least Squares Mean | Standard Error | Units on a scale | Baseline up to Month 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Time to First Psychiatric Hospitalization | A time-to parameter looking only at 1 component event of treatment failure: psychiatric hospitalization. Time to first psychiatric hospitalization was admission date of the psychiatric hospitalization recorded in the "Assessment of Treatment Failure - Psychiatric Hospitalization." | eITT population included all ITT participants who had their study assessments for time period between randomization date and eITT end point. The eITT end point for paliperidone palmitate was the last injection date+28 days and for oral antipsychotics was the last prescription date + the number of days' supply + 1 day. | Posted | Median | 95% Confidence Interval | Days | From date of randomization up to Month 15 |
| ||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score During Overall Treatment Duration | The CGI-S rating scale was a 7-point global assessment of symptom severity with scores determined by clinician as follows: 1=Not ill, 2=Very Mild, 3= Mild, 4= Moderate, 5= Marked, 6= Severe, and 7= Extremely Severe. The higher the score the worse the illness. | eITT population. 'N' (number of participants analyzed) signifies participants who were evaluable for this outcome measure. | Posted | Least Squares Mean | Standard Error | Units on a scale | Baseline up to Month 15 |
|
| |||||||||||||||||||||||||||||
| Primary | Percentage of Participants in Each Event Category of First Treatment Failure | First treatment failure was a composite endpoint consisting of any of the following events: arrest/incarceration, psychiatric hospitalization, discontinuation (D/C) of antipsychotic treatment due to safety or tolerability, treatment supplementation with another antipsychotic due to inadequate efficacy, discontinuation of antipsychotic treatment due to inadequate efficacy, increase in level of psychiatric services to prevent imminent psychiatric hospitalization, suicide. A Treatment Failure Event Monitoring Board (EMB), blinded to individual participant treatment assignment, determined the occurrence and date of the first treatment failure event. Percentage of participants who experienced treatment failure due to any event and for each specific category of event were assessed. | eITT population included all ITT participants who had their study assessments for time period between randomization date and eITT end point. The eITT end point for paliperidone palmitate was the last injection date+28 days and for oral antipsychotics was the last prescription date + the number of days' supply + 1 day. | Posted | Number | percentage of participants | From date of randomization up to Month 15 |
|
Not provided
Intent to Treat (ITT) population included all participants who were randomly assigned to treatment and who received at least 1 dose of their randomly assigned study treatment.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Paliperidone Palmitate | Intramuscular injection, 234 milligram (mg) on Day 1, 156 mg on Day 8, followed by flexible monthly maintenance dosing as per investigator's discretion starting on Day 38 up to 15 months. | 42 | 226 | 178 | 226 | ||
| EG001 | Oral Antipsychotics | One of 7 oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone) that the investigator specified as appropriate for the participant was administered as per clinical practice for up to 15 months. | 53 | 218 | 155 | 218 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiac Failure Congestive | Cardiac disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Coronary Artery Disease | Cardiac disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Haematemesis | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Intestinal Obstruction | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Asthenia | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Chest Pain | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Drug Withdrawal Syndrome | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Non-cardiac Chest Pain | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Sudden Death | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Acquired Immunodeficiency Syndrome | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Cellulitis | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Cholecystitis Infective | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| H1N1 Influenza | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| HIV Infection | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Otitis Media | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Pneumonia | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Sepsis | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Wound Infection | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Accidental Overdose | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Alcohol Poisoning | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Gun Shot Wound | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hip Fracture | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Intentional Overdose | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Lower Limb Fracture | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Overdose | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Perirenal Haematoma | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Traumatic Brain Injury | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Traumatic Lung Injury | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Rhabdomyolysis | Musculoskeletal and connective tissue disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Gastric Cancer Stage III | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Akathisia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Cerebellar Ataxia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Convulsion | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dystonia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Encephalitis | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Epilepsy | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Facial Paresis | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Ischaemic Stroke | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Presyncope | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Syncope | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Stillbirth | Pregnancy, puerperium and perinatal conditions | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Acute Psychosis | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Aggression | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Alcohol Withdrawal Syndrome | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Alcoholism | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Delusion | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Depression Suicidal | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Depressive Symptom | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Factitious Disorder | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hallucination | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hallucination, Auditory | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hallucinations, Mixed | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Homicidal Ideation | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Mania | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Mental Status Changes | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Paranoia | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Polysubstance Dependence | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Psychotic Behaviour | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Psychotic Disorder | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Schizoaffective Disorder Bipolar Type | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Schizophrenia | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Schizophrenia, Paranoid Type | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Substance Abuse | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Suicidal Ideation | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Suicide Attempt | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Renal Failure Acute | Renal and urinary disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Acute Respiratory Distress Syndrome | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Pulmonary Embolism | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Status Asthmaticus | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Deep Vein Thrombosis | Vascular disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA Version 12.0 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hyperprolactinaemia | Endocrine disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Abdominal Discomfort | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dry Mouth | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dyspepsia | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Salivary Hypersecretion | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Toothache | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Fatigue | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Injection Site Pain | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Irritability | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Pain | General disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Influenza | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Joint Sprain | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Laceration | Injury, poisoning and procedural complications | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Blood Prolactin Increased | Investigations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Semen Volume Decreased | Investigations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Weight Increased | Investigations | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Abnormal Weight Gain | Metabolism and nutrition disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Increased Appetite | Metabolism and nutrition disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Back Pain | Musculoskeletal and connective tissue disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Musculoskeletal Stiffness | Musculoskeletal and connective tissue disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Pain in Extremity | Musculoskeletal and connective tissue disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Akathisia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dyskinesia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Dystonia | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Extrapyramidal Disorder | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Headache | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Sedation | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Somnolence | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Tremor | Nervous system disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Agitation | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Anxiety | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Depression | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hallucination, Auditory | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Insomnia | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Libido Decreased | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Schizophrenia | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Suicidal Ideation | Psychiatric disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Amenorrhoea | Reproductive system and breast disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Erectile Dysfunction | Reproductive system and breast disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Galactorrhoea | Reproductive system and breast disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Nasal Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA Version 12.0 | Non-systematic Assessment |
| |
| Hypertension | Vascular disorders | MedDRA Version 12.0 | Non-systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Director, Clinical Development | Janssen Research & Development | ClinicalTrialDisclosure@its.jnj.com |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068882 | Paliperidone Palmitate |
| D018967 | Risperidone |
| D010546 | Perphenazine |
| D000068180 | Aripiprazole |
| D000069348 | Quetiapine Fumarate |
| D000077152 | Olanzapine |
| ID | Term |
|---|---|
| D007555 | Isoxazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |
| D011744 | Pyrimidinones |
| D010640 | Phenothiazines |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010879 | Piperazines |
| D015363 | Quinolones |
| D011804 | Quinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D003987 | Dibenzothiazepines |
| D013841 | Thiazepines |
| D013846 | Thiepins |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
Not provided
Not provided
| Male |
|
|
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
| Participants |
|
|
One of 7 oral antipsychotics (aripiprazole, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, and risperidone) that the investigator specified as appropriate for the participant was administered as per clinical practice for up to 15 months. |
|
|